Inspira Technologies Oxy BHN (IINN) has released an update.
Inspira Technologies Oxy BHN has unveiled the INSPIRA Cardi-ART, a groundbreaking portable device designed to deliver oxygen to the brain during cardiac arrest situations, which could significantly improve survival rates. With the potential to target a combined global market worth $58.8 billion, the company plans to seek FDA approval by 2026. The device, currently in development, aims to leverage Inspira’s advanced blood oxygenation and monitoring technologies to offer lifesaving support for cardiac arrest patients both in and outside hospitals.
For further insights into IINN stock, check out TipRanks’ Stock Analysis page.
